NEUROINMUNOLOGIA
Charing Cross Hospital
Hammersmith, Reino UnidoCharing Cross Hospital-ko ikertzaileekin lankidetzan egindako argitalpenak (2)
2009
-
Safety and immunogenicity of a new formulation of interferon β-1a (Rebif® New Formulation) in a Phase IIIb study in patients with relapsing multiple sclerosis: 96-week results
Multiple Sclerosis, Vol. 15, Núm. 2, pp. 219-228
2005
-
MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS)
Multiple Sclerosis, Vol. 11, Núm. 4, pp. 433-440